Overview
I'm a third year PhD student working on developing new caner virotherapy platforms.
In my lab, supervised by Professor Alan Parker, we develop new adenovirus-based vectors, which can be used as cancer therapies, gene-therapy- or vaccine vectors. I am funded by CRUK and co-supervised by Dr Carly Bliss and Professor Awen Gallimore.
In my thesis, titled "Development of Precision Virotherapies Capapble of Evading Host Anti-Vector Immunity" I will be exploring how population immunity to Ad5, the most commonly used Adenovirus vector, can be circumvented to better deliver therapies to patients.
Publication
2024
- Wallace, R., Bliss, C. M. and Parker, A. L. 2024. The immune system - A double-edged sword for adenovirus-based therapies. Viruses 16(6), article number: 973. (10.3390/v16060973)
2021
- Nestic, D., Bozinovic, K., Pehar, I., Wallace, R., Parker, A. L. and Majhen, D. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)
Articles
- Wallace, R., Bliss, C. M. and Parker, A. L. 2024. The immune system - A double-edged sword for adenovirus-based therapies. Viruses 16(6), article number: 973. (10.3390/v16060973)
- Nestic, D., Bozinovic, K., Pehar, I., Wallace, R., Parker, A. L. and Majhen, D. 2021. The revolving door of adenovirus cell entry: not all pathways are equal. Pharmaceutics 13(10), article number: 1585. (10.3390/pharmaceutics13101585)